



COMPANY OVERVIEW

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. **CDX-101**, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. **CDX-301**, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. We also have a commercial business unit that markets ZanthoSyn[®], a physician recommended astaxanthin dietary supplement for inflammatory health. We sell ZanthoSyn[®] primarily through wholesale and e-commerce channels.

RECENT NEWS

Cardax Reports Q3 2020 Results

Nov 13 2020, 4:30 PM EST

Cardax Reports Q2 2020 Results

Aug 14 2020, 5:00 PM EDT

STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Market Cap	1.15m
Last Price	\$1.50
52-Week Range	\$1.15 - \$19.00

11/27/2020 12:10 PM EST

INVESTOR RELATIONS

Cardax, Inc.
T: (808) 457-1400
investors@cardaxpharma.com

MANAGEMENT TEAM

David G. Watumull
President and CEO, Director

David M. Watumull
Chief Operating Officer

Paresh N. Soni, M.D., Ph.D.
Chief Clinical and Regulatory Strategist &
SAB Member

Gilbert M. Rishton, Ph.D.
Chief Science Officer

Timothy J. King, Ph.D.
Vice President, Research

John B. Russell
Chief Financial Officer and Treasurer

CARDAX, INC.

2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.